Cancer Vaccine Statistics in US 2026 | Trials, Survival Rates & Key Facts

Cancer Vaccines in America 2026

Cancer vaccines reached a genuine milestone on August 19, 2026, when Merck and Moderna announced that their Phase 3 INTerpath-001 trial met its primary endpoint — marking the first-ever positive Phase 3 result for both an individualized neoantigen therapy and an mRNA-based cancer treatment. The trial tested intismeran autogene (also called V940 or mRNA-4157), a personalized vaccine built from a patient’s own tumor DNA, in combination with Keytruda (pembrolizumab) for patients with completely resected stage IIB-IV melanoma. The companies now plan to present full data at an upcoming medical meeting and begin engaging regulators on a formal approval submission.

This breakthrough builds on years of incremental progress in a field that, until now, had produced only a handful of FDA-approved therapeutic vaccines despite decades of research investment. As of 2026, just three therapeutic cancer vaccines — Provenge, BCG, and T-VEC — hold FDA approval, even as more than 120 mRNA cancer vaccine trials are actively underway across melanoma, pancreatic, lung, and colorectal cancers. This report compiles the most current, verified statistics on cancer vaccine development, clinical trial results, and survival outcomes in the United States, current as of August 2026.

Interesting Facts About Cancer Vaccines in the US 2026

Source: Merck/Moderna joint press release, August 19, 2026; OncLive; BioSpace; Cancer Research Institute 2026 Immunotherapy Report

The INTerpath-001 result matters less for any single statistic than for what it represents structurally: it is the first Phase 3 trial of any kind to succeed for a personalized neoantigen cancer vaccine, a technology platform researchers have pursued for over a decade without a definitive late-stage win. The trial’s Phase 2b predecessor, KEYNOTE-942, had already shown a 49% reduction in risk of recurrence or death and a 59% reduction in risk of distant metastasis at five-year follow-up — figures presented at the 2026 ASCO Annual Meeting that gave researchers strong reason to expect the larger Phase 3 trial would succeed, though the companies have been explicit that INTerpath-001’s own detailed hazard ratios and survival percentages were not yet disclosed in the initial topline announcement.

The gap between just 3 FDA-approved therapeutic vaccines and the 120-plus active trials currently underway illustrates how difficult this field has historically proven, even as investment and scientific interest have grown steadily. Cancer vaccines face a fundamentally harder challenge than infectious-disease vaccines: rather than training the immune system to recognize a foreign virus or bacterium with consistent, shared features, therapeutic cancer vaccines must teach the immune system to recognize a patient’s own mutated cells — a target that varies from tumor to tumor and often changes as the cancer evolves, which is precisely why personalized, patient-specific vaccines like intismeran autogene represent such a significant technical advance over earlier, non-personalized approaches.

FDA-Approved Cancer Vaccine Statistics in the US

Source: Cancer Research Institute; American Cancer Society; PharmExec

The three FDA-approved therapeutic vaccines each work through entirely different mechanisms, reflecting the field’s decades-long search for a workable approach. BCG, first approved in 1990 and originally developed as a tuberculosis vaccine in the 1920s, stimulates general immune activation in the bladder rather than targeting specific tumor antigens. Sipuleucel-T (Provenge), approved in 2010, takes a genuinely personalized approach — a patient’s own immune cells are removed, exposed to a prostate cancer-associated protein, activated, and reinfused. T-VEC, approved in 2015, uses a modified herpes virus injected directly into melanoma lesions to trigger both local tumor destruction and a broader immune response.

Separately, preventive cancer vaccines — which protect against viral infections known to cause cancer rather than treating existing tumors — have achieved far broader real-world impact. Since HPV and hepatitis B infections are linked to an estimated 15-20% of cancers globally, the Gardasil vaccine against HPV, first approved in 2006, has become one of modern medicine’s clearest cancer-prevention success stories, contributing to a documented 79% drop in cervical precancers among vaccinated young women, detailed further in the Cervical Cancer Statistics in US report.

Cancer Vaccine Clinical Trial Pipeline Statistics 2026

Source: Melanoma vaccine R&D landscape analysis, 442 clinical trials (PMC, 2026); NCBI meta-analysis of mRNA vaccine trials

A systematic analysis of 442 melanoma and cancer vaccine clinical trials conducted through August 2025 reveals a field still heavily weighted toward early-stage research: nearly 64% of all trials remain in Phase I or Phase I/II testing, while only 6.1% have advanced to Phase III — the stage INTerpath-001 just cleared. That “translational funnel effect,” as researchers described it, is compounded by a 22.9% trial termination rate, meaning nearly a quarter of cancer vaccine trials never reach completion, whether due to disappointing early results, funding constraints, or strategic pivots by sponsoring companies.

Geographically, the field remains heavily concentrated in wealthy nations, with 69% of melanoma vaccine trials conducted in the United States and minimal participation from Asia, Africa, and Latin America — a pattern that mirrors broader disparities in clinical trial access across oncology generally. Among vaccine platform types, peptide and recombinant protein vaccines (186 trials) and cellular vaccines (151 trials) still outnumber the newer nucleic acid-based platforms (58 trials) that include the mRNA technology behind INTerpath-001, though the nucleic acid category is widely viewed as the field’s fastest-growing and most promising segment following the August 2026 announcement.

mRNA Cancer Vaccine Clinical Results Statistics 2026

Source: BioSpace, August 19, 2026; welovelmc.com Cancer Vaccine Tracker, July 2026; Memorial Sloan Kettering, April 2026

The Phase 2b KEYNOTE-942 results that preceded INTerpath-001 remain the most detailed publicly available efficacy data for this vaccine platform, and they are genuinely striking: a 49% reduction in the risk of recurrence or death, a 59% reduction in risk of distant metastasis, and an exploratory 53% improvement in overall survival, all compared against Keytruda alone. Safety data from the same trial showed immune-related toxicities in roughly 45% of combination-therapy patients, but critically, no grade 4 or 5 adverse events were reported, with the most common side effects limited to fatigue, injection-site pain, and chills — all classified as mild to moderate.

A separate, smaller trial offers an even more striking survival signal in a historically difficult cancer: Memorial Sloan Kettering’s personalized mRNA vaccine for pancreatic cancer, developed with BioNTech, found that nearly 90% of patients whose immune systems responded to the vaccine were still alive up to six years after their final treatment — a remarkable figure given that pancreatic cancer’s overall five-year survival rate sits at just 13%, according to the American Cancer Society’s 2026 Cancer Statistics report. That result remains from a small Phase 1 trial, however, and larger randomized studies will be needed before it can be considered confirmed at a population level.

Cancer Type Survival Rates Relevant to Current Vaccine Research

Source: theworlddata.com Cancer Survival Rate Statistics by Type 2026; American Cancer Society Cancer Facts & Figures 2026; Merck/Moderna, August 2026

Melanoma’s relatively high ~94% overall five-year survival rate might seem to make it a less urgent target for vaccine research than lower-survival cancers like pancreatic or lung cancer, but that headline figure masks the real clinical problem the INTerpath program targets: patients with completely resected, high-risk stage IIB-IV melanoma — the population studied in INTerpath-001 — face substantially elevated recurrence risk even after successful surgery, with most recurrences occurring within the first two years and skewing toward dangerous, distant metastatic spread rather than local regrowth. It’s this adjuvant, recurrence-prevention setting, rather than treatment of already-metastatic disease, where the vaccine has shown its clearest benefit so far.

The broader pipeline reflects a deliberate strategic sequencing: having established proof-of-concept in melanoma — a cancer type with relatively well-characterized tumor antigens and a track record of responding to immunotherapy — the same INTerpath program is now expanding into non-small cell lung cancer, bladder cancer, and renal cell carcinoma through eight additional Phase 2 and Phase 3 trials, while earlier-phase KRAS-targeted mRNA vaccines for pancreatic and colorectal cancer remain in Phase 2 testing with data anticipated later in 2026. Full detail on how survival rates vary by cancer type, stage, and demographic factors — context essential for understanding which patient populations stand to benefit most from these emerging therapies — is available in the Cancer Survival Rate Statistics by Type report.

US Cancer Burden Context Statistics 2026

Source: Cancer Statistics in the US 2026; American Cancer Society Cancer Facts & Figures 2026

Cancer vaccine breakthroughs like INTerpath-001 arrive against a backdrop of broader, sustained progress in American cancer outcomes: the overall five-year survival rate across all cancer types has climbed from roughly 49% in the 1970s to approximately 69-70% today, a trajectory that has averted an estimated 4.5 million deaths since 1991 through the combined effect of reduced smoking rates, expanded screening programs, and successive waves of treatment innovation, most recently including immunotherapy. Full context on how the 2026 cancer burden breaks down by cancer type, demographic group, and stage at diagnosis is available in the Cancer Statistics in the US report.

With 10-15% of cancer patients now receiving some form of immunotherapy — a category that includes checkpoint inhibitors, CAR-T cell therapy, and, increasingly, personalized cancer vaccines — and that share expanding rapidly, the INTerpath-001 result is likely to accelerate an already fast-moving shift in how oncologists approach high-risk, resected cancers going forward. Whether personalized mRNA vaccines can replicate this melanoma success across the harder-to-treat cancer types where they’re now being tested — pancreatic, lung, and colorectal cancer chief among them — remains the central open question shaping cancer vaccine research through the remainder of 2026 and beyond.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE